Natera said it is expanding Signatera’s footprint in minimal residual disease testing and preparing to enter early cancer detection after multiple recent regulatory wins. In the last four months, the company received FDA approval for Signatera as a companion diagnostic in muscle-invasive bladder cancer, was included in NCCN guidelines for the same indication, and won Japan approval for colorectal cancer through PMDA. Natera also reported Europe’s IVD Regulation certification for Signatera across multiple cancers, positioning the assay for broader commercial distribution beyond the U.S. The company signaled that VEGA, a randomized de-escalation study in Japan, is expected to read out in 2027. The set of approvals matters because MRD tests are increasingly being used to influence treatment intensity; Natera’s expansion adds scale to a platform that already holds a dominant presence in MRD while testing new evidence pathways for clinical adoption.